Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Elizabeth Dudnik
Observed names:
E. Dudnik,
Elizabeth R. Dudnik
Institutions:
Ben-Gurion University of the Negev,
Assuta Medical Center
Observed institutions:
Ben-Gurion University of the Negev,
Cedars-Sinai Medical Center,
United States Food and Drug Administration,
Tel Aviv University,
Technion – Israel Institute of Technology,
Rabin Medical Center,
Assuta Medical Center,
Rambam Health Care Campus,
Bnai Zion Medical Center
show all 9
ORCID:
0000-0001-6971-3576
Observed ORCID:
0000-0001-6971-3576
OpenAlex ID:
A5021797186
BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors
2018
·
Elizabeth Dudnik
, Nir Peled
, et al.
·
Journal of Thoracic Oncology
·
228
PDF
Neoadjuvant Osimertinib for Resectable EGFR -Mutated Non–Small Cell Lung Cancer
2025
·
Jianxing He
, Masahiro Tsuboi
, et al.
·
Journal of Clinical Oncology
·
153
Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases
2016
·
Elizabeth Dudnik
, Shlomit Yust-Katz
, et al.
·
Lung Cancer
·
138
Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study
2019
·
Jair Bar
, Gal Markel
, et al.
·
European Journal of Cancer
·
113
Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data
2017
·
Elizabeth Dudnik
, Mor Moskovitz
, et al.
·
Lung Cancer
·
113
ALK-Rearranged Non–Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism
2016
·
Alona Zer
, Mor Moskovitz
, et al.
·
Clinical Lung Cancer
·
103
Clinical Impact of Hybrid Capture–Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer
2016
·
Anna Belilovski Rozenblum
, Maya Ilouze
, et al.
·
Journal of Thoracic Oncology
·
84
PDF
Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi)
2018
·
Elizabeth Dudnik
, Elias Bshara
, et al.
·
Lung Cancer
·
75
Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: A randomised phase II study
2012
·
Gil Bar-Sela
, Mira Wollner
, et al.
·
European Journal of Cancer
·
71
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data
2021
·
Elizabeth Dudnik
, Mor Moskovitz
, et al.
·
OncoImmunology
·
67
Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors
2021
·
Oded Icht
, Naama Darzi
, et al.
·
Journal of Thrombosis and Haemostasis
·
65
Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC)
2020
·
Shira Sherman
, Ofer Rotem
, et al.
·
Lung Cancer
·
63
Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival
2019
·
Anna May Suidan
, Laila Roisman
, et al.
·
Journal of Global Oncology
·
62
Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung
2021
·
Elizabeth Dudnik
, Samuel Kareff
, et al.
·
Journal for ImmunoTherapy of Cancer
·
56
PDF
The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer
2018
·
Smadar Laufer-Geva
, Anna Belilovski Rozenblum
, et al.
·
Journal of Thoracic Oncology
·
47
Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer
2021
·
Yosef Landman
, Oded Jacobi
, et al.
·
OncoImmunology
·
40
PDF
RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients
2016
·
Michal Sarfaty
, Assaf Moore
, et al.
·
Clinical Lung Cancer
·
40
Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program
2022
·
Oliver Illini
, Hannah Fabikan
, et al.
·
Therapeutic Advances in Medical Oncology
·
35
PDF
The Relationship of Diabetes Mellitus to Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer
2021
·
Oded Jacobi
, Yosef Landman
, et al.
·
Oncology
·
35
GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients
2020
·
Nir Peled
, Roni Gillis
, et al.
·
Lung Cancer
·
34
Treatment Beyond Progression with Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer
2020
·
Daniel Reinhorn
, Oded Jacobi
, et al.
·
Immunotherapy
·
33
Immune-related Neutropenia Following Treatment With Immune Checkpoint Inhibitors
2019
·
Inbar Finkel
, Michal Sternschuss
, et al.
·
Journal of Immunotherapy
·
32
FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)
2022
·
Ari Raphael
, Elizabeth Dudnik
, et al.
·
Journal of Clinical Medicine
·
28
PDF
Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study
2021
·
Nir Peled
, Waleed Kian
, et al.
·
Neuro-Oncology Advances
·
28
PDF
dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50%
2021
·
Liran Holtzman
, Mor Moskovitz
, et al.
·
Clinical Lung Cancer
·
26
Show more works
View as search
Works count:
116
Citation count:
2,202
H-index:
25
I10-index:
43
Year
Topic
Type